20240729_EPMT_Laporan Informasi dan Fakta Material_31688576_lamp2.pdf

                              i       I




    \I ,,                                                                        / II/                                                                                           J1: k r , Juf 1 29, 2024
                                  •                                                                                                                                                     0 k Cod,:.: Prl1T
                                                                                   I         I     'I


    I
                                                                                         I
                                                                                             fl 0,
                                                            I           I ll1                -i1   I

                I                           7
                    •
                    •                      I                    I   I                                     1 Mod I.

                            " I t1                   I l,
    F                                 ,         1   h 1 of t                    Con p n , h r               y       . is los tt    iollowi ng infcirn1ation or material facts:
                                                                                                                                             1




        I                             I u r or P ,IJII Compan ,                                                 •
                                                                                                                •           P . ns ail Put ra M     r ding Tbk
                                      Fi Id                                                                     •
                                                                                                                              holesale of Ph rm, ceu ical □,rugs and Medica,I Devices
                                                                                                                .
                                                                                                                •
                                                                                                                            021- 6822 22
                                                                                                                •
                                                                                                                            sugianto.sugi n o@ ns,eval.com;
                                                                                                                            Investor. lations@enseval.co,m

                            D te of E 1en                                                               Jul 29,202·
                                                                                                        Submissi,on of information regarding the signing of he Sharehold,ers Agreemen
    j
                            T pe of ,Vlateri I                                                          (SHA) in order to es abllsh a joint ven ure com1p,an name,d PT Livzon Pharma
                            In orma ion o Facts                                                         Indonesia. This transaction is not a Material Transaction or Conflict of Interest
                                                                                                        Transaction based on the Financiad Services Au hority Regulation.
                                                                                                        In order to comply wlth Financial Services A1uthority Regulation o. 31/POJK.04/2015
                                                                                                        dated Dec:ember 16, 20 5 concerning Di,sclosure of a ,erial Information or Facts by
                                                                                                        Issuers or Public Com,panies, the Com1pa,ny conveys that:
                                                                                                        a. The Company h ou,gh its subsidiary, PT Global Ch1emindo, Megatrading (GCM)
                                                                                                             together ith Lian SGP IHol1dling Pte. Ltd. (Lian SGIP}, a wholly owned subsidiary of
                            D scription of r �at rial                                                        Livzon Pharmaceutical ,Group Inc. signed a Shar, ehol ,ders Agree1ment (SH1A) in
    3
                            Informat1on or Facts                                                             order o establish a jo,·nt venture company;
                                                                                                        b. The signing of th1e SHA • s carried out o July 29', 2024, GCM and Lian SGP
                                                                                                             agreed to estaibliish a 1new comp,any called Pl li1vzon Ph1arma Indonesia wh1ich is
                                                                                                             domiciled I1n, C 1entral Jakar �a, engaged In he active pharmace,u i,caJ lngredien1 s
                                                                                                             indus ry wi, h an initia,1 investment of IDR 650 billion J and th1e composition of
                                                                                                             issued and fuHy pa11d capi1ta·I of 80% by Lian SGP an1d 20% by GCM, resp,ec Ivel
                            Th impa,ct of t e incident,
                            informa ,on, or mat rial'                                                   This ,collaboratio,n, s e .. pec1 ed to str ngthen the 1Co,mpa,ny 1 s focus on the prod1uction
                             ,act on he operational,                                                    of active pha maceutical ing edients (A,Pl) an 1d ether pharmaceutical 1ingredients for
                            la , f1nan ial condi ion, or                                                 h      par market l by look·ng at the potential use, of th1e ,domes ic m rlke in the
                            bus,n ss con· inuity of · he                                                fu ure.
                            Is ue or Pu,blic Company


                        an, ou for our att ntion and cooperation.


    Sine r J ,
    P n        I u r




     Su       SH
    ·Corporate S ere ary




                                      u
J           I           I              �                                                                                tJ 0, Inc on, Sit   I I I                           o () 1) I